MM-111: Phase II started

Merrimack began an open-label, international Phase II trial of IV MM-111 in up to 180 patients who have failed first-line metastatic or locally advanced therapy. Patients with a HER2 score of 2+ or 3+ on the HercepTest and/or a positive fluorescence in situ hybridization (FISH) status for HER2 - a group that traditionally receives trastuzumab-based therapy - will receive MM-111 plus paclitaxel and trastuzumab or paclitaxel and trastuzumab. Patients with HER2 score of 2+ on the HercepTest and a negative FISH status for HER2 - a group that is usually not treated with HER2-targeted therapy - will receive MM-111 plus paclitaxel or paclitaxel alone. ...